Notice to Investors in Amarin Corp. plc's (AMRN) July 10, 2013 Public Offering: Wolf Popper LLP Announces Anticipated Filing of Amended Complaint Against Amarin Corp. plc (NASDAQ: AMRN)

NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Wolf Popper LLP, lead counsel in the In re Amarin Corp. plc Securities Litigation, pending in the U.S. District Court for the District of New Jersey (Civil Action No. 13-cv-06663), is scheduled to file an amended complaint in the class action on September 19, 2014.  That complaint will assert claims against Amarin and individual defendants arising out of the federal securities laws.  The allegations in the action relate to defendants' alleged misrepresentations with respect to prospects for FDA approval of Amarin's Vascepa drug for the ANCHOR indication.

On July 8, 2013, Amarin filed a Prospectus Supplement for the issuance of 21.7 million American Depositary Shares (ADSs) through underwriters Citigroup Global Markets Inc. and Jefferies LLC.  Investors who purchased Amarin ADSs on the secondary offering through the underwriters on or after July 9, 2013, are specifically urged to contact Wolf Popper LLP to discuss their legal rights to pursue claims in the amended complaint.

For more information, please contact:

Robert C. Finkel, Esq.
Tel.: 212.759.4600 or 877.370.7703 (toll free)
Fax: 212.486.2093 or 877.370.7704 (toll free)
Email:             [email protected]
website:         www.wolfpopper.com

Attorney Advertising:  Prior Results Do Not Guarantee A Similar Outcome.

SOURCE Wolf Popper LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED